{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:51:10Z","timestamp":1760403070658,"version":"build-2065373602"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Medical Award Foundation","award":["YXJL-2023-0270-0303"],"award-info":[{"award-number":["YXJL-2023-0270-0303"]}]},{"name":"Shanghai Sixth People's Hospital Fund","award":["ynts202307"],"award-info":[{"award-number":["ynts202307"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10067-025-07619-1","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T10:41:49Z","timestamp":1754476909000},"page":"3829-3833","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Suboptimal methotrexate utilization in Chinese patients with inflammatory arthritis: data from a Chinese center"],"prefix":"10.1007","volume":"44","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8876-4205","authenticated-orcid":false,"given":"Sheng-Ming","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"7619_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82:223356","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"7619_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N et al (2022) Group for research and assessment of Psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18(8):465\u2013479","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"7619_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO et al (2024) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis 83(6):706\u2013719","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7619_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/jdv.20501","volume":"39","author":"A Nosbaum","year":"2025","unstructured":"Nosbaum A, Machado G (2025) Methotrexate for atopic dermatitis: the right dosing and best-performance administration route. J Eur Acad Dermatol Venereol 39(2):249\u2013250","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"7619_CR5","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3899\/jrheum.151212","volume":"43","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Bykerk VP, Aassi M, Schiff M (2016) Adherence and persistence with methotrexate in rheumatoid arthritis: a systematic review. J Rheumatol 43(11):1997\u20132009","journal-title":"J Rheumatol"},{"issue":"4","key":"7619_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/ard.2009.113308","volume":"69","author":"E Lie","year":"2010","unstructured":"Lie E, van der Heijde D, Uhlig T et al (2010) Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 69(4):671\u2013676","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7619_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10067-014-2546-x","volume":"33","author":"E Nikiphorou","year":"2014","unstructured":"Nikiphorou E, Negoescu A, Fitzpatrick JD et al (2014) Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. Clin Rheumatol 33(5):609\u2013614","journal-title":"Clin Rheumatol"},{"issue":"9","key":"7619_CR8","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/acr2.11079","volume":"1","author":"K Michaud","year":"2019","unstructured":"Michaud K, Vrijens B, Tousset E et al (2019) Real-world adherence to oral methotrexate measured electronically in patients with established rheumatoid arthritis. ACR Open Rheumatol 1(9):560\u2013570","journal-title":"ACR Open Rheumatol"},{"issue":"4","key":"7619_CR9","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1016\/S2665-9913(23)00070-X","volume":"5","author":"H Tamai","year":"2023","unstructured":"Tamai H, Ikeda K, Miyamoto T et al (2023) Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial. Lancet Rheumatol 5(4):e215\u2013e224","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"7619_CR10","first-page":"213","volume":"59","author":"HF Hope","year":"2020","unstructured":"Hope HF, Hyrich KL, Anderson J et al (2020) The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. Rheumatology (Oxford) 59(1):213\u2013223","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"7619_CR11","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1136\/annrheumdis-2017-211268","volume":"76","author":"C Gaujoux-Viala","year":"2017","unstructured":"Gaujoux-Viala C, Rincheval N, Dougados M, Combe B, Fautrel B (2017) Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort. Ann Rheum Dis 76(12):2054\u20132060","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"7619_CR12","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1136\/annrheumdis-2016-209383","volume":"75","author":"J Dur\u00e1n","year":"2016","unstructured":"Dur\u00e1n J, Bockorny M, Dalal D, LaValley M, Felson DT (2016) Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review. Ann Rheum Dis 75(9):1595\u20131598","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"7619_CR13","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1136\/ard.2008.092668","volume":"68","author":"K Visser","year":"2009","unstructured":"Visser K, van der Heijde D (2009) Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68(7):1094\u20131099","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7619_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1563-6","volume":"20","author":"YZ Zhou","year":"2018","unstructured":"Zhou YZ, Zhao LD, Chen H et al (2018) Comparison of the impact of tripterygium wilfordii Hook F and methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study. Arthritis Res Ther 20(1):70","journal-title":"Arthritis Res Ther"},{"key":"7619_CR15","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2147\/DDDT.S207226","volume":"13","author":"Y Huang","year":"2019","unstructured":"Huang Y, Wang H, Chen Z et al (2019) Efficacy and safety of total glucosides of paeony combined with methotrexate and leflunomide for active rheumatoid arthritis: a meta-analysis. Drug Des Devel Ther 13:1969\u20131984","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"7619_CR16","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/rheumatology\/key369","volume":"58","author":"SK Appani","year":"2019","unstructured":"Appani SK, Devarasetti PK, Irlapati RVP, Rajasekhar L (2019) Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis. Rheumatology (Oxford) 58(5):869\u2013873","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"7619_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40744-015-0011-1","volume":"2","author":"DB DiBenedetti","year":"2015","unstructured":"DiBenedetti DB, Zhou X, Reynolds M, Ogale S, Best JH (2015) Assessing methotrexate adherence in rheumatoid arthritis: a cross-sectional survey. Rheumatol Ther 2(1):73\u201384","journal-title":"Rheumatol Ther"},{"issue":"11","key":"7619_CR18","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/acr.22383","volume":"66","author":"JR Curtis","year":"2014","unstructured":"Curtis JR, Zhang J, Xie F et al (2014) Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken) 66(11):1604\u20131611","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"7619_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0003-4967(24)43387-6","volume":"60","author":"J Hill","year":"2001","unstructured":"Hill J, Bird H, Johnson S (2001) Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 60(9):869\u2013875","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7619_CR20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2014-206504","volume":"75","author":"GS Hazlewood","year":"2016","unstructured":"Hazlewood GS, Thorne JC, Pope JE et al (2016) The comparative effective ness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis 75(6):1003\u20131008","journal-title":"Ann Rheum Dis"},{"key":"7619_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.5293","volume":"1","author":"AG Levy","year":"2018","unstructured":"Levy AG, Scherer AM, Zikmund-Fisher BJ, Larkin K, Barnes GD, Fagerlin A (2018) Prevalence of and factors associated with patient nondisclosure of medically relevant information to clinicians. JAMA Netw Open 1:e185293","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07619-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07619-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07619-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:20:20Z","timestamp":1760365220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07619-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7619"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07619-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}